Key statistics
On Thursday, Idorsia Ltd (0RQE:LSE) closed at 0.7458, 8.47% above its 52-week low of 0.6875, set on Nov 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.732 |
---|---|
High | 0.7458 |
Low | 0.7458 |
Bid | 0.721 |
Offer | 0.7965 |
Previous close | 0.7253 |
Average volume | 85.87k |
---|---|
Shares outstanding | 189.33m |
Free float | 121.09m |
P/E (TTM) | -- |
Market cap | 136.79m CHF |
EPS (TTM) | -1.68 CHF |
Data delayed at least 15 minutes, as of Nov 21 2024 16:37 GMT.
More ▼
Announcements
- Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions
- Idorsia announces financial results for the first nine months of 2024
- New data on aprocitentan to be presented at the ASN Kidney Week 2024
- Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024
- New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024
- Amended terms of Idorsia’s 2024 convertible bonds become effective
- Idorsia announces financial results for the first half 2024
- Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call
- Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension
- Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds
More ▼